Showing 3221-3230 of 5773 results for "".
- Oculis Begins Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-begins-phase-3-optimize-2-trial-of-ocs-01-for-the-treatment-of-inflammation-and-pain-following-cataract-surgery/2482022/Oculis Holding announced 'First Patient First Visit' (FPFV) in the OCS-01 phase 3 OPTIMIZE-2 trial for the treatment of inflammation and pain following cataract surgery. Data from the phase 3 OPTIMIZE-2 trial is intended to support the company’s NDA submission to the FDA. If ap
- Nordic Pharma Completes Acquisition of Visant Medical; Plans to Launch Lacrifill in the US for Dry Eye Diseasehttps://modernod.com/news/nordic-pharma-completes-acquisition-of-visant-medical-plans-to-launch-lacrifill-in-the-us-for-dry-eye-disease/2482021/Amring Pharmaceuticals, a subsidiary of Nordic Group BV (Nordic Pharma), announced the completion of its acquisition of Visant Medical. Financial terms of the deal were not disclosed. The companies say the acquisition unites Nordic Pharma's pharmaceutical e
- Pixium Vision: Date Scheduled for Decision on Adoption of a Sale Planhttps://modernod.com/news/pixium-vison-date-scheduled-for-decision-on-adoption-of-a-sale-plan/2482020/Pixium Vision SA announced that following a hearing on Monday, the Paris Commercial Court will issue its decision on January 16, 2024 on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings. In the event of the opening of judicial l
- Ocugen's OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of RP Associated with RHO Mutationshttps://modernod.com/news/ocugens-ocu400-receives-regenerative-medicine-advanced-therapy-rmat-designation-for-treatment-of-rp-associated-with-rho-mutations/2482019/Ocugen announced that the FDA has granted RMAT designation to Ocugen’s investigational product OCU400 for the treatment of retinitis pigmentosa (RP) associated with RHO mutations. “RMAT designation is a significant accomplishment for the OCU400 clinical develo
- Reichert to Distribute Imaging and Dry Eye Treatment Devices in the United Stateshttps://modernod.com/news/reichert-to-distribute-imaging-and-dry-eye-treatment-devices-in-the-united-states/2482016/Reichert Technologies, a business of AMETEK Inc., announced an exclusive partnership with SBM Sistemi of Italy to distribute SBM’s imaging and dry eye assessment and treatment devices in the United States. Financial terms of the deal were not disclosed. </
- Oculis Commences Stage 2 of Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in DMEhttps://modernod.com/news/oculis-announces-first-patient-first-visit-in-phase-3-diamond-1-trial-of-ocs-01-eye-drop-in-dme/2482015/Oculis Holding announced that the 'First Patient First Visit (FPFV)' in stage 2 of its phase 3 DIAMOND-1 trial evaluating OCS-01 for the treatment of DME. DIAMOND-1 is a phase 3, two-stage, double-masked, randomized, multicenter trial to assess the efficacy and sa
- Carl Zeiss Meditec to Acquire Dutch Ophthalmic Research Center (DORC)https://modernod.com/news/carl-zeiss-meditec-to-acquire-dutch-ophthalmic-research-center-dorc/2482014/In a move to expand its position in the vitreo-retinal surgery segment and strengthen its position in the ophthalmic medical device category globally, Carl Zeiss Meditec announced it has entered into an agreement to acquire 100% of the shares in Dutch Ophthalmic Research Cente
- Clearside Biomedical Completes Randomization in Phase 2b Clinical Trial of CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-completes-randomization-in-phase-2b-clinical-trial-of-cls-ax-in-wet-amd/2482013/Clearside Biomedical announced it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in wet age-related macular degeneration (AMD). Topline data results are expected in the third quarter of 2024. “As we continue
- Prevent Blindness President & CEO Jeff Todd to Lead 2024 National Health Council Board of Directorshttps://modernod.com/news/prevent-blindness-president-ceo-jeff-todd-to-lead-2024-national-health-council-board-of-directors/2482007/At the National Health Council (NHC) annual membership meeting, Jeff Todd, President & Chief Executive Officer of Prevent Blindness, was named the Chair of the NHC Board of Directors for 2024. “Jeff Todd is an excellent choice to lead our Board in 2024,” said R
- Ophtec Launches Precizon Go IOL for Enhanced Intermediate Visionhttps://modernod.com/news/ophtec-launches-precizon-go-iol-for-enhanced-intermediate-vision/2482002/Ophtec announced the launch of the Precizon Go, a hybrid acrylic IOL designed to provide distance and enhanced intermediate vision. The lens is designed to offer natural vision at far and enhanced intermediate vision, without compromising the quality of vision at any